Rapport Therapeutics (RAPP) Total Current Liabilities (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Total Current Liabilities of $17.9 million for Q1 2026, up 90.74% year-over-year from $9.4 million in Q1 2025, and down 6.05% quarter-over-quarter from $19.0 million in Q4 2025.
Rapport Therapeutics (RAPP) Total Current Liabilities (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Total Current Liabilities for 4 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 90.74% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $17.9 million (up 90.74% YoY), while the FY2025 annual figure was $19.0 million, up 117.28% from the prior year.
- Total Current Liabilities declined to $17.9 million in Q1 2026 per RAPP's latest filing, from $19.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $19.0 million in Q4 2025 and bottomed at $7.1 million in Q3 2024.
- Historically, Total Current Liabilities has averaged $11.7 million across 4 years, with a median of $9.4 million in 2025.
- Annual changes were most pronounced in 2024 — Total Current Liabilities decreased 0.41% — and 2025, when it surged 117.28%.
- Rapport Therapeutics' Total Current Liabilities stood at $8.8 million in 2023, then decreased by 0.41% to $8.8 million in 2024, then soared by 117.28% to $19.0 million in 2025, then slipped by 6.05% to $17.9 million in 2026.
- Business Quant data shows RAPP's Total Current Liabilities at $17.9 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 28.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.42 Mn |
| Mar 31, 2026 | 17.90 Mn |
| Dec 31, 2025 | 19.05 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Jun 30, 2025 | 11.88 Mn |
| Mar 31, 2025 | 9.38 Mn |
| Dec 31, 2024 | 8.77 Mn |
| Sep 30, 2024 | 7.10 Mn |
| Jun 30, 2024 | 8.10 Mn |
| Dec 31, 2023 | 8.80 Mn |